BeStock  
Stocks › Biotechnology › TBPH

Theravance Biopharma(Delisted) TBPH

US equityMarket cap rank #3323Biotechnology
$17.03 +$0.00 (0.00%)
Market closed · Oct 8, 12:00 am ET
Open$0.00
Prev close$17.03
Day range$0.00 – $0.00
Volume0.00
Market cap$884.18M
P/E (TTM)16.4
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$20.73M-20.9% YoY
Operating profit$1.84M+167.6% YoY
Net profit-$5.90M-110.8% YoY
Diluted EPS-$0.11-110.2% YoY
Free cash flow-$6.97M-103.3% YoY
Operating cash flow-$6.97M

Revenue, last 8 quarters

$16.9MSep '24$18.8MDec '24$15.4MMar '25$26.2MJun '25$20.0MSep '25$45.9MDec '25$17.7MMar '26$20.7MJun '26

Net profit, last 8 quarters

$-12.7MSep '24$-15.5MDec '24$-13.6MMar '25$54.8MJun '25$3.6MSep '25$61.0MDec '25$-4.9MMar '26$-5.9MJun '26

Diluted EPS by quarter

-0.26Sep '24-0.31Dec '24-0.27Mar '251.08Jun '250.07Sep '251.15Dec '25-0.10Mar '26-0.11Jun '26

Free cash flow by quarter

$-5.2MSep '24$-1.1MDec '24$43.0MMar '25$208.0MJun '25$-6.5MSep '25$-6.1MDec '25$73.3MMar '26$-7.0MJun '26

Annual revenue

$71.9MFY20$55.3MFY21$51.3MFY22$57.4MFY23$64.4MFY24$107.5MFY25

Profitability & balance sheet

Operating margin9.2%
Net margin51.6%
Return on equity20.9%
Return on assets12.0%
Return on invested capital14.0%
Current ratio13.54
Liabilities / assets38.3%
Cash & investments$387.66M
Total debt$27.77M
Net cash (debt)$359.88M
Free cash flow / sales51.5%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $20.73M $17.70M $107.46M $45.89M $19.99M
Total Operating Revenue $20.73M $17.70M $107.46M $45.89M $19.99M
Operating Expense $18.89M $23.55M $111.07M $25.88M $26.45M
Selling and Admin Expenses $14.18M $17.72M $73.65M $18.52M $18.33M
Research & Development $4.71M $5.83M $37.41M $7.36M $8.11M
Operating Profit $1.84M -$5.85M -$3.60M $20.01M -$6.46M
Net Non-Operating Interest Income (Expense) $3.49M $3.01M $7.71M $3.06M $3.57M
Non-Operating Interest Income $3.49M $3.01M $10.17M $3.64M $4.14M
Non-Operating Interest Expense $0.00 $0.00 $2.46M $582,000.00 $573,000.00
Other Income (Expense) -$10.12M -$3.63M $125.14M $50.00M –
Special Income (Charges) -$10.12M -$3.63M $75.14M $0.00 $0.00
-Less:Restructuring and Mergern & Acquisition $10.12M $3.63M – – –
-Gain on Sale of Property/Plant/Equipment $0.00 – $75.14M $0.00 $0.00
Pretax Profit -$4.79M -$6.47M $129.25M $73.07M -$2.89M
Tax $1.11M -$1.54M $23.35M $12.04M -$6.50M
Net Profit -$5.90M -$4.93M $105.90M $61.02M $3.62M
Profit from Continuing Operations -$5.90M -$4.93M $105.90M $61.02M $3.62M
Net Income to Parent Company -$5.90M -$4.93M $105.90M $61.02M $3.62M
Net Income to Common Stockholders -$5.90M -$4.93M $105.90M $61.02M $3.62M
Basic EPS -$0.11 -$0.10 $2.10 $1.20 $0.07
Diluted EPS -$0.11 -$0.10 $2.06 $1.15 $0.07
-Less:Impairment of Capital Assets – – $0.00 $0.00 $0.00
Other Non-Operating Income (Expenses) – – $50.00M – –

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $469.77M $472.31M $485.57M $485.57M $415.46M
Total Current Assets $416.66M $417.63M $418.46M $418.46M $354.70M
Cash and Cash Equivalents & Short-Term Investments $387.66M $394.67M $315.36M $315.36M $329.68M
-Cash and Cash Equivalents $219.77M $288.10M $167.81M $167.81M $174.77M
-Short Term Investments $167.89M $106.57M $147.55M $147.55M $154.91M
Receivables $20.38M $15.58M $95.54M $95.54M $18.27M
-Accounts Receivable $20.38M $15.58M $45.54M $45.54M $18.27M
Other Current Assets $8.62M $7.38M $7.56M $7.56M $6.75M
Total Non-Current Assets $53.11M $54.68M $67.11M $67.11M $60.76M
Net PPE $27.10M $28.54M $30.27M $30.27M $31.71M
-Gross PPE $27.10M $28.54M $54.09M $54.09M $31.71M
Investments and Advances $0.00 $0.00 $11.13M $11.13M $3.03M
Other Non-Current Assets $26.01M $26.14M $25.72M $25.72M $26.03M
Total Liabilities $180.07M $181.72M $188.85M $188.85M $182.78M
Total Current Liabilities $30.77M $31.78M $38.30M $38.30M $37.41M
Payables $652,000.00 $6.39M $7.86M $7.86M $6.29M
-Accounts Payable $652,000.00 $1.10M $2.57M $2.57M $2.21M
-Total Tax Payable $0.00 $5.29M $5.29M $5.29M $4.07M
Current Accrued Expenses $19.32M $14.64M $19.50M $19.50M $20.21M
Short-Term Debt and Capital Lease Obligation $10.80M $10.75M $10.95M $10.95M $10.91M
-Current Capital Lease Obligation $10.80M $10.75M $10.95M $10.95M $10.91M
Total Non-Current Liabilities $149.30M $149.94M $150.55M $150.55M $145.37M
Long Term Accounts Payable and Other Payables $88.49M $87.15M $85.68M $85.68M $79.17M
Long Term Debt and Capital Lease Obligation $27.77M $29.75M $31.76M $31.76M $33.68M
-Long Term Capital Lease Obligation $27.77M $29.75M $31.76M $31.76M $33.68M
Other Non-Current Liabilities $33.04M $33.04M $33.11M $33.11M $32.53M
Total Equity $289.71M $290.59M $296.72M $296.72M $232.68M
Stockholders' Equity $289.71M $290.59M $296.72M $296.72M $232.68M
Capital Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
-Common Stock $1,000.00 $1,000.00 $1,000.00 $1,000.00 $1,000.00
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.16B $1.16B $1.16B $1.16B $1.15B
Retained Earnings -$870.46M -$864.56M -$859.63M -$859.63M -$920.65M
Gains/Losses Not Affecting Retained Earnings -$76,000.00 -$62,000.00 $61,000.00 $61,000.00 $32,000.00
-Other Receivables – – $50.00M $50.00M –
-Accumulated Depreciation – – -$23.82M -$23.82M –
-Available for Sale Securities – – $11.13M $11.13M $3.03M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow -$6.97M $73.28M $238.54M -$6.06M -$6.51M
Net cash flow from continuing operations -$6.97M $73.28M $238.54M -$6.06M -$6.51M
Net Income from Continuing Operations -$5.90M -$4.93M $105.90M $61.02M $3.62M
Depreciation & Depletion & Amortization $506,000.00 $835,000.00 $2.81M $196,000.00 $636,000.00
Deferred Tax -$218,000.00 -$3.00M -$11.52M $30,000.00 $994,000.00
Other Non-Cash Items $26,000.00 $42,000.00 $2.37M $588,000.00 $551,000.00
Change in Working Capital -$7.37M $75.83M $120.47M -$72.38M -$16.88M
-Change in Receivables -$4.80M $79.95M -$27.10M -$77.27M $3.65M
-Change in Prepaid Assets -$1.25M $1.67M -$3.29M -$814,000.00 -$1.18M
-Change in Payables and Accrued Expense -$1.05M -$6.34M $4.34M -$3.11M -$14.51M
-Change in Other Current Assets $330,000.00 $1.34M $143.09M $223,000.00 -$372,000.00
-Change in Other Current Liabilities -$1.94M -$2.27M -$7.05M -$1.89M -$1.86M
-Change In Other Working Capital $1.33M $1.47M $10.48M – –
Net cash flow from investing -$60.40M $52.59M -$105.28M $588,000.00 -$100.25M
Net Cash Flow from Continuing Investing Activities -$60.40M $52.59M -$105.28M $588,000.00 -$100.25M
Net Investment Purchase and Sale -$60.40M $52.59M -$105.24M $596,000.00 -$100.25M
Financing Cash Flow -$967,000.00 -$5.58M -$3.25M -$1.49M -$400,000.00
Net Cash Flow from Continuing Financing Activities -$967,000.00 -$5.58M -$3.25M -$1.49M -$400,000.00
Net Common Stock Issuance -$2.10M -$5.82M -$4.01M -$1.98M -$678,000.00
Proceeds from Stock Option Exercised $1.14M $241,000.00 $766,000.00 $488,000.00 $278,000.00
Ending Cash Balance $220.60M $288.94M $168.64M $168.64M $175.61M
Net Change in Cash -$68.34M $120.30M $130.01M -$6.97M -$107.15M
Beginning Cash Balance $288.94M $168.64M $38.63M $175.61M $282.76M
Free Cash Flow -$6.97M $73.28M $238.50M -$6.07M -$6.51M
Gain/Loss from Continuing Operations – – $35,000.00 $0.00 $0.00
Net PPE Purchase and Sale – – -$42,000.00 -$8,000.00 $0.00

Discussion

No comments yet — be the first to weigh in on TBPH.

Leave a comment

Scroll to Top